BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9235086)

  • 1. [Multidrug resistance (MDR) in oncology].
    Souvirón Rodríguez A; Ruiz Gómez MJ; Morales Moreno JA; Martínez Morillo M
    An Med Interna; 1997 Mar; 14(3):145-53. PubMed ID: 9235086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of multidrug resistance in cancer chemotherapy.
    Nooter K; Stoter G
    Pathol Res Pract; 1996 Jul; 192(7):768-80. PubMed ID: 8880878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
    Krishna R; Mayer LD
    Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
    Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
    Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
    Jachez B; Loor F
    Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance.
    Márián T; Szabó G; Goda K; Nagy H; Szincsák N; Juhász I; Galuska L; Balkay L; Mikecz P; Trón L; Krasznai Z
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1147-54. PubMed ID: 12830325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
    Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressors and reversion of multidrug-resistance.
    Aouali N; Eddabra L; Macadré J; Morjani H
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):61-70. PubMed ID: 15978826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressors as multidrug resistance reversal agents.
    Morjani H; Madoulet C
    Methods Mol Biol; 2010; 596():433-46. PubMed ID: 19949935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
    Kaye SB
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833.
    Naito M; Tsuruo T
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S20-4. PubMed ID: 9272129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of passive transbilayer drug movement in multidrug resistance and its modulation.
    Eytan GD; Regev R; Oren G; Assaraf YG
    J Biol Chem; 1996 May; 271(22):12897-902. PubMed ID: 8662680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein.
    Archinal-Mattheis A; Rzepka RW; Watanabe T; Kokubu N; Itoh Y; Combates NJ; Bair KW; Cohen D
    Oncol Res; 1995; 7(12):603-10. PubMed ID: 8704277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin.
    Michieli M; Damiani D; Michelutti A; Melli C; Ermacora A; Geromin A; Fanin R; Russo D; Baccarani M
    Haematologica; 1996; 81(4):295-301. PubMed ID: 8870372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells.
    Nadali F; Pourfathollah AA; Alimoghaddam K; Nikougoftar M; Rostami S; Dizaji A; Azizi E; Zomorodipour A; Ghavamzadeh A
    Hematology; 2007 Oct; 12(5):393-401. PubMed ID: 17852455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance.
    Le Bot MA; Kernaleguen D; Robert J; Berlion M; Riché C
    Cancer Chemother Pharmacol; 1994; 35(1):53-8. PubMed ID: 7987977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [SDZ PSC 833: a novel modulator of MDR].
    Covelli A
    Tumori; 1997; 83(5 Suppl):S21-4. PubMed ID: 9446255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein.
    Kang CD; Ahn BK; Jeong CS; Kim KW; Lee HJ; Yoo SD; Chung BS; Kim SH
    Exp Cell Res; 2000 Apr; 256(1):300-7. PubMed ID: 10739677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in sensitivity to UVC, UVB and UVA radiation of a multidrug-resistant cell line overexpressing P-glycoprotein.
    Trindade GS; Capella MA; Capella LS; Affonso-Mitidieri OR; Rumjanek VM
    Photochem Photobiol; 1999 Jun; 69(6):694-9. PubMed ID: 10378008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of multidrug resistance: lessons from clinical oncology.
    Bates SF; Chen C; Robey R; Kang M; Figg WD; Fojo T
    Novartis Found Symp; 2002; 243():83-96; discussion 96-102, 180-5. PubMed ID: 11990784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.